Full-Time

Inside Sales Representative 2

Posted on 9/10/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

$57.9k - $85.4k/yr

New Mexico, USA + 48 more

More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | California, USA | Washington, DC, USA | Vermont, USA | Wyoming, USA | Los Angeles, CA, USA | Texas, USA | Jackson Township, NJ, USA | Florida, USA | Waterbury, CT, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Fallon, MT, USA | Arizona, USA | Concord, NH, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Colorado, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Oklahoma City, OK, USA | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Wisconsin, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Missouri, USA | Ohio, USA | Indiana, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA

Remote

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Customer Service
Requirements
  • Requires a demonstrated history of successful application of consultative selling skills in a diverse customer marketplace resulting in improved customer sales.
  • Broad training in fields such as business administration, accountancy, sales, marketing, computer sciences or similar vocations generally obtained through completion of a four-year bachelor's degree program or equivalent combination of experience and education are required.
  • Normally requires five (5) plus years directly related and progressively responsible sales experience.
  • Experience in the pharmaceutical industry, retail and alternate care segments is desirable.
  • Working knowledge of retail and alternate care industries, trends, and challenges facing customers
  • Ability to communicate effectively both orally and in writing, and adapt communication style to various audiences
  • Ability to actively listen and influence others with different points of view
  • Strong organizational agility, working across teams internally to achieve a common goal.
  • Advanced understanding of financial concepts relevant to maximizing sales profit (e.g. profit and loss statements, value)
  • Excellent customer service skills to address potential issues through channels such as Customer Care without compromising selling-focused conversation
  • Strong organizational skills; attention to detail
  • Ability to adapt to change, and successfully monitor multiple tasks without sacrificing quality or timeliness of work
  • Strong presentation skills
  • Strong time management skills; ability to schedule customer appointments in advance.
Responsibilities
  • Meets or exceeds specific business sales targets, set in cooperation with the Sales Director, for revenue, profit and margin growth with existing primary and secondary customers in the community physician pharmacy segment within a specific customer assignment (territory) via account penetration.
  • Maintain relationships with existing customers within the Sales Executive’s segment to ensure continued business and successful renewals to facilitate sales growth.
  • Meets business targets related to the sale of specific solutions. Cencora's suite of offerings includes, but is not limited to, solutions such as PODIS Plus, Cubixx MD, Infodive and Consulting.
  • Ensure ongoing contract compliance from existing customers by reinforcing the total value of the prime vendor agreement (PVA), and proactively addressing/resolving any reasons for non-compliance. Negotiates Prime Vendor Agreements (PVA) with current customers and implement new PVAs resulting in continual retention of profitable accounts in the individual sales assignment.
  • Monitors and analyzes reports and data to measure profitability growth specialty and biosimilars, develops and implements strategies to ensure continued success of that growth.
  • Achieves monthly sales/activity goals established in conjunction with department manager. This may include but not limited to call volume, % of calls leading to an order, order volume and revenue.
  • Leads the onboarding of new customers within the assigned segments, as well as implementation of customer solutions, by effectively collaborating with functional departments to ensure full adoption, value realization and an ongoing excellent customer experience.
  • Partners across functional and organizational lines by engaging and working directly and collaboratively with subject matter experts during the sales process to execute sales expansion and maintenance strategies using Cencora's Suite of Offerings to address customer specific needs.
  • In cooperation with the Sales Director create an annual strategic plan for achieving your business goals, utilizing sales reporting tools ongoing to identify and analyze opportunities to expand current customer business.
  • Creates an operationally efficient daily territory call plan. Effectively and efficiently manages the assigned territory with a regular call cycle that results in the delivery of appropriate/defined customer touches while also making off-cycle, discretionary calls, as situations require.
  • Continually maintains and inputs account activity/results information and tracks interactions in the CRM and other appropriate sales management tools.
  • Develops and maintains a strong base of working knowledge of the community physician markets through the use of ABC training, District Director coaching, display of market/customer business curiosity, industry information and company literature, which allows for successful execution of ABC sales strategies and commercial insights.
Desired Qualifications
  • Experience in the pharmaceutical industry, retail and alternate care segments is desirable.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE